Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

New Treatment Approaches for Breast and Ovarian Cancer

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
New Treatment Approaches for Breast and Ovarian Cancer
A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer.
Vicky Makker
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
New Treatment Approaches for Breast and Ovarian Cancer
Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study
Kathleen Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
New Treatment Approaches for Breast and Ovarian Cancer
Phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953)
Khanh T Do
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
New Treatment Approaches for Breast and Ovarian Cancer
OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
Mark E Robson
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
New Treatment Approaches for Breast and Ovarian Cancer
Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial
Nicholas C. Turner
Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
New Treatment Approaches for Breast and Ovarian Cancer
MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2- advanced breast cancer - Results from the preplanned final PFS analysis
Matthew P Goetz
Mayo Clinic, Rochester, MN, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
New Treatment Approaches for Breast and Ovarian Cancer
Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC)
Mafalda Oliveira
Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, Spain
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7